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Abstract Tendons regenerate poorly due to a dense extracel-
lular matrix and low cellularity. Cellular therapies aim to im-
prove tendon repair using mesenchymal stem cells and
tenocytes; however, a current limitation is the low prolifera-
tive potential of tenocytes in cases of severe trauma. The pur-
pose of this study was to develop a method useful in veteri-
nary medicine to improve the differentiation of Peripheral
Blood equine mesenchymal stem cells (PB-MSCs) into
tenocytes. PB-MSCs were used to study the effects of the
addition of some growth factors (GFs) as TGFβ3
(transforming growth factor), EGF2 (Epidermal growth fac-
tor), bFGF2 (Fibroblast growth factor) and IGF-1 (insulin-like
growth factor) in presence or without Low Level Laser
Technology (LLLT) on the mRNA expression levels of genes
important in the tenogenic induction as Early Growth
Response Protein-1 (EGR1), Tenascin (TNC) and Decorin
(DCN). The singular addition of GFs did not show any influ-
ence on the mRNA expression of tenogenic genes whereas the
specific combinations that arrested cell proliferation in favour
of differentiation were the following: bFGF2 + TGFβ3 and
bFGF2 + TGFβ3 + LLLT. Indeed, the supplement of bFGF2
and TGFβ3 significantly upregulated the expression of Early
Growth Response Protein-1 and Decorin, while the use of
LLLT induced a significant increase of Tenascin C levels. In
conclusion, the present studymight furnish significant sugges-
tions for developing an efficient approach for tenocyte induc-
tion since the external administration of bFGF2 and TGFβ3,
along with LLLT, influences the differentiation of PB-MSCs
towards the tenogenic fate.
Keywords Growth factors . Low level laser technology .
Mesenchymal stromal cells . Tenocytes . Tenogenic induction
Introduction
Tendons are made of dense connective tissue and present low
cellularity and low vascularity. These properties confer char-
acteristics such as stiffness and elasticity (Brehm et al. 2012;
Smith et al. 2013; Patruno and Martinello 2014), which are
essential in transmitting forces between muscles and bones
(Freedman et al. 2014). However, the not-vascularized nature
and low number of tenocytes, reduce the self-healing and re-
generative potential of tendons (Jiang et al. 2014; Veronesi
et al. 2015). In veterinary medicine, several therapies are used
to improve tendon regeneration although long rehabilitation
periods are needed and relapses are frequent (Riley 2008;
Spaas et al. 2012). In order to augment tendon healing, inno-
vative techniques are being used to treat tendon lesions, in-
cluding tissue engineering and cell therapies (Delincé and
Ghafil 2012) such as platelet-rich plasma (PRP), growth fac-
tors (GFs) (Maia et al. 2009), mesenchymal stem cells (MSCs)
(Brehm et al. 2012) and low level laser irradiation (LLLI)
(Sperandio et al. 2014; Iacopetti et al. 2015). Since it should
exists a synergy action between GFs present in PRP and
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low-level laser technology (LLLT), the aim of this study was
to verify their influence in reprogramming MSCs into
tenocytes fate.
PRP is an important source of autologous GFs (Abate et al.
2012) such as PDGF (Platelet-Derived Growth Factor), VEGF
(Vascular endothelial growth factor), thromboxane, fibronec-
tin/vitronectin, TGFβ (transforming growth factor), EGF
(Epidermal growth factor), FGF (Fibroblast growth factor)
(Anitua et al. 2015), IGF (insulin-like growth factor)
(Schär et al. 2015) and cell fractions that can accelerate
wound healing, decrease the inflammatory reaction and
promote regeneration of affected tissues (Dimauro et al.
2014). In horses autologous platelet concentrates (APCs)
are recently intensively studied in order to find the most
appropriate protocols for clinical purposes (Hessel et al.
2015). Moreover, it has been demonstrated that several
GFs, such as EGF, bFGF, PDGF-BB and TGF-β1, in-
fluence tenogenic differentiation and extracellular matrix
production (Goncalves et al. 2013).
MSCs can be isolated from several sources (Martinello
et al. 2010; Martinello et al. 2011; Zhu et al. 2013,
Toupadakis et al. 2010), are able to generate several types of
mature and differentiated cells and to improve tendinopathy
treatment (Smith et al. 2013). In equine medicine, bone mar-
row and peripheral blood are commonly used (Crovace et al.
2010; Martinello et al. 2013; Broeckx et al. 2014a, 2014b).
MSCs isolated from horse peripheral blood (PB-MSCs) are
able to differentiate into diverse mesenchymal lineages and
could be used in cell-based therapies for the treatment of ten-
don, ligament, and bone pathologies as well as cartilage de-
fects (Koerner et al. 2006; Giovannini et al. 2008; Martinello
et al. 2010; Martinello et al. 2011; Spaas et al. 2013; Barberini
et al. 2014).
LLLT is a therapy being used by veterinarians to reduce
inflammation and pain and accelerate tissue healing (Hawkins
and Abrahamse 2006). In vivo and in vitro studies have dem-
onstrated the stimulatory capacity of low-level laser energy on
cell populations obtained from different tissues (Posten et al.
2005). Chen et al. (2015) showed that LLLT is able to stimu-
late proliferation and collagen synthesis of tenocytes as well as
keratinocyte proliferation. Pyo et al. (2013) demonstrated that
LLLI increase cell proliferation and promote the expression of
BMP-2, osteocalcin, and TGFβ1 hypothesizing an influence
in bone regeneration through a stimulatory effect on osteo-
blasts favouring their growth and maturation.
Although these new treatments have shown some positive
effects on tendon regeneration, researchers are starting to com-
bine different strategies to improve tendon regenerative capa-
bilities. Another recent approach for enhancing tendon regen-
eration is the tenogenic induction ofMSCs before clinical use.
Using this methodology, Pietschmann et al. (2013) showed
that tenocytes demonstrated increased biomechanical and his-
tologic regenerative properties in a full-size tendon defect
when compared to non-induced MSCs. Unfortunately, autol-
ogous tenocytes have a limited proliferative potential and eth-
ic committees from many countries prohibit invasive collec-
tion of tendon tissue to obtain tenocytes (Tan et al. 2012). Our
hypothesis was to evaluate the synergic action of GFs, usually
present in PRP preparations, and LLLT for inducing the dif-
ferentiation of low immunogenic MSCs (Broeckx et al.
2014a, 2014b) towards the tenogenic fate; therefore, we have
used different combinations of GFs, with and without LLLT,
in order to check the gene expression of EGR1 (Early growth
response protein 1), Tenascin C (TNC) and Decorin (DCN),
all crucial genes involved in tenogenesis (Pajala et al. 2009;
Tao et al. 2015; Dunkman et al. 2013).
Materials and methods
Isolation and culture of PB-MSCs
Twenty millilitres of blood were collected into sterile EDTA
(Ethylenediaminetetraacetic acid) tubes from the external jug-
ular vein of four adult mares between five and seven years of
age. Animal Ethics Committee approval numbers and date
are: EC_2012_001 (21–11-2012) and EC_2014_001, (17–
02-2014) by Global Stem Cell Technology, GST, Belgium;
EC_2014_020 (07–04-2014) by Faculty of Veterinary
Medicine, Ghent University, Belgium.
Blood samples were transported to the GST-ANACURA
laboratory at room temperature within 4 h of sampling. Blood
samples were centrifuged at 1000 g for 20 min at room tem-
perature (RT) and the buffy coat collected and diluted 1:2 with
Phosphate Buffered Saline (PBS). The cell suspension was
layered on Percoll gradient (density 1.080 g/mL; GE
Healthcare) and centrifuged at 600 g for 15 min at RT. The
interphase was collected, washed three times with PBS and
centrifuged at 200 g for 10 min at RT (Spaas et al. 2013). The
putative MSCs were seeded in a T75 flask (BD Falcon) with
an expansion medium (Exp) made as follows: Dulbecco’s
Modified Eagle Medium (DMEM, Euroclone ECM0728L),
20 % fetal calf serum (FCS, (Euroclone ECS0180L),
1 % antibiotics/antimycotics (Euroclone ECB3001D)
and 10−11 M dexamethasone (Sigma Aldrich). The me-
dium was refreshed twice a week and cells cultured at
37 °C and 5 % CO2. At 70 % of confluence, the cells
were trypsinized with 0.25 % trypsin- ethylenediamine-
tetraacetic acid (Euroclone ECB3051D) passage 0 (P0)
and further cultured for 10 additional passages
(P1 → P10) with the same medium, but without dexa-
methasone (Sigma Aldrich). Cells were used at specific
passages (P1-P10 for PDT experiment, P5 and P10 for
Flow cytometry and P5 for GF and laser experiments)
as described below.
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Population doubling time (PDT)
PDT was calculated from P1 to P10 using the following for-
mula: PDT = cell culture time (T)/cell doubling time (CDT). T
was expressed as days from Ni to Nf, where Ni is the initial
and Nf the final number of cells for each passage and CDT
was obtained with the following formula: CDT = ln(Nf/Ni)/
ln(2) (Hoynowski et al. 2007).
Flow cytometry
For quality control purposes, immunophenotypic characteri-
zation (Spaas et al. 2013) of all donor PB-MSCs was per-
formed at P5 and P10. Briefly, PB-MSCs were tested for the
stem cell Cluster of Differentiation (CD) markers CD29,
CD44 and CD90 and for the adult blood cell (negative)
markers CD45, major histocompatibility complex (MHC)
type II and monocyte/macrophage marker by flow cytometry.
The cells were prepared as described in Spaas et al. (2013).
The following combinations of markers and their respective
clones were assessed: CD29-APC (TS2/16, Biolegend),
CD44-FITC (CVS18, AbD Serotec), CD90 (DH24A,
VMRD) + IgG1-PE-Cy7 (Biolegend)/as positive subset;
CD45-PeCy5.5 (F10-89-4, AbD Serotec), mono- & macro-
cyte marker-Alexa 488 (MAC387, AbD Serotec), +
MHCII-PE (CVS20, AbD Serotec) as negative subset.
Control isotypes were tested for each marker to define the
threshold (the range for isotype controls was defined at 0–
1 % of positive signals). The samples were analyzed on a
FACSCanto II (BD Biosciences) instrument, equipped with
two lasers (488 nm solid state and a 633 nm HeNe laser).
The optimal settings for the MSC were determined by
Compbeads Plus beads. Flow cytometer performance was
monitored on a daily basis by Cytometer Setup & Tracking
beads (BD Biosciences). The data were analyzed with
FacsDiva software.
Addition of growth factors (GFs)
PB-MSCs obtained from four donor horses were seeded, at
passage 5, each in T25 flasks (1500 cells/cm2) to test the
effects of the addition of some growth factors (GFs) on the
mRNA expression levels of genes important in the tenogenic
induction such as EGR1, TNC and DCN (see below the Real
Time PCR method). The GFs added were the following:
TGFβ3 (transforming growth factor), EGF2 (Epidermal
growth factor), bFGF2 (Fibroblast growth factor) and IGF-1
(insulin-like growth factor). The latter GFs were tested singu-
larly with and without LLLT (data not shown) in order to
confirm previous observations (Schneider et al. 2011) that
described no changes when GFs were tested alone.
However, our preliminary results indicated that bFGF2 in-
creased, although not significantly, the expression of the tested
genes; consequently, and also because bFGF2 is essential in
the tenogenic differentiation and wound repair, it has been
decided to always use it in the following GFs combinations
(see the panel below).
Combination Growth factors
1 Exp
2 Exp LLLT
3 Exp bFGF2
4 Exp bFGF2 LLLT
5 Exp bFGF2 TGFβ3
6 Exp bFGF2 TGFβ3 LLLT
7 Exp bFGF2 IGF1
8 Exp bFGF2 IGF1 LLLT
9 Exp bFGF2 EGF2
10 Exp bFGF2 EGF2 LLLT
The expansion medium (Exp) was therefore used alone
(combination N.1) or with LLLT (combination N.2) or sup-
plemented with: bFGF2 (combination N.3), bFGF2 and LLLT
(combination N.4), bFGF2 and TGFβ3 (combination N.5),
bFGF2, TGFβ3 and LLLT (combination N.6), bFGF2 and
IGF1 (combination N.7), bFGF2, IGF1 and LLLT (combina-
tion N.8), bFGF2 and EGF2 (combination N.9), bFGF2,
EGF2 and LLLT (combination N.10). All GFs are by
Sigma-Aldrich and were added to the medium at 10 ng/ml.
PB-MSCs were cultured in duplicate to evaluate the effect of
the GFs treatment alone and in addition to LLLT. Cells were
cultured in supplemented media for five days, with the medi-
um refreshed at day three. Five days after seeding cells
reached 70 % confluency and were trypsinized, counted and
frozen at −80 °C with 90 % expansion medium with 10 %
DMSO (Dimethyl sulfoxide) for subsequent Real Time poly-
merase chain reaction (Real time-PCR) analyses. These exper-
iments were repeated four times.
Low level laser technology (LLLT)
PB-MSCs seeded at 1500 cells/cm2 in T25 flasks were con-
ditioned with GFs, as previously described in the paragraph
above, and submitted to LLLT (ASAlaser, M6 handpiece)
equipped with combined, synchronized and overlapping con-
tinuous and pulsed emissions emitted by a single handpiece.
The emission was produced by an InGa(Al)As diode laser
with the following parameters: for continuous wave the wave-
length was of 660 nm while for pulsed laser diode the wave-
length was of 905 nm (peak optical power 25W). A daily dose
of 5 J/cm2 for 2 min performed by the same operator. The first
irradiation was performed 24 h after seeding to allow cell
attachment and conditioning of GFs. Subsequently, LLLT
was performed once a day up to the fifth day after seeding;
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when cells reached 70 % of confluence they were trypsinized,
counted and frozen.
Cell count
Cells were trypsinized and collected after each treatment with
GFs and LLLT. The number were determined by Burker
chamber counting and the cells were marked with Trypan
Blue (Sigma B-7021) in order to calculate the average number
of dead and live cells. This evaluation allowed discerning the
effect of treatments between the arrest of proliferation and cell
death.
RNA isolation and gene expression analysis
Total RNA extraction was performed using TRIzol (Life
Technologies) reagent following the manufacturer’s instruc-
tions. RNA was quantified on a Nanodrop (Thermo
Scientific) spectrophotometer and a complementary single
strand DNA (cDNA) was synthesized from 2 μg of purified
RNA to perform real time-PCR using the ABI 7500 Real
Time PCR system (Applied Biosystem). The relative expres-
sion of the following genes was used to evaluate tenogenic
induction after five days of treatments: EGR1, DCN and TNC.
Each sample was tested in triplicate and untreated PB-MSCs
were used as a calibrator sample. The 2-ΔΔct method was used
to analyze and normalize the RNA expression of the target
genes with respect to the endogenous housekeeping gene
Glyceraldehyde- 3- phosphate dehydrogenase (GAPDH).
PCR primers were designed using Primer Express 3.0 soft-
ware (Applied Biosystems).
Statistical analysis
Normally distr ibuted data were expressed as the
mean ± standard deviation. Normality of the data was con-
firmed using the Kolmogorov–Smirnov test (α = 5 %).
Statistical analyses were performed using the paired Student
t test (SPSS software, version 11.0, SPSS, IBM). The level of
statistical significance was set at P ≤ 0.05 for all analyses.
Results
Flow cytometric analysis of isolated PB-MSCs
PB-MSCs were successfully isolated from peripheral blood of
four healthy horses. The expression profile of cell-surface an-
tigen in adherent PB-MSCs was evaluated by flow cytometry
in cell samples at P5 (Fig. 1a) and P10 (Fig. 1b). Cells from
the four horses were uniformly positive for adhesion markers
CD29 (100 % ± 0 at P5 and P10), CD44 (92 % ± 4 at P5,
99.3 % ± 0.5 at P10) and CD90 (100 % ± 0 at P5 and P10). In
addition, the analysis demonstrated less than 5% positivity for
the hematopoietic lineage marker as CD45 (1.7 % ± 0.6 at P5,
1.2 % ± 0.3 at P10), for the leukocytes markers Mo/Ma
(0.8 % ± 0.3 at P5, 1.4 % ± 2 at P10) and for the MHCII
(0 % ± 0 at P5 and P10). In Fig. 1c, the CD percentages of
different markers used in the study are summarized.
Population doubling time of isolated PB-MSCs
To examine PDT of PB-MSC samples (n = 4), the prolifera-
tion potential was measured according to the passage number
(from P1 to P10). The PDT showed an initial lag time (sup-
plemental figure), but PDT was relatively constant from P3
until P10.
Cell proliferation of PB-MSCs treated with GFs
and LLLT
Figure 2 shows the concentration of dead cells (dark grey bars)
and live cells (light grey bars) detected in cell culture after
each treatment. All combination of GFs caused the same cy-
totoxicity (dead cells 31.5 ± 14.2, Fig. 2) and it was slightly
greater than control medium and laser treatment. The combi-
nations of bFGF2 + TGFβ3 and bFGF2 + TGFβ3 + LLLT,
arrested cell proliferation compared to control cells and other
GFs treatments (Fig. 2 light grey bars) without increasing the
cell death. This data indicate that TGFβ3 influences the pro-
liferation of MSCs, while EGF2 and IGF1 do not modify cell
growth.
MRNA expression of EGR1, TNC and DCN
PB-MSCs were used to test the effects of the addition of some
GFs (TGFβ3, IGF1, bFGF2 and EGF2) on the mRNA expres-
sion levels of genes involved in the tenogenic differentiation
such as EGR1, TNC and DCN. TGFβ3, IGF1, bFGF2 and
EGF2 were previously tested individually with and without
LLLT (data not shown) without obtaining any significant re-
sults; therefore, we started to use combinations of GFs with
and without LLLT (see panel in the material and methods).
Figure 3a and 3c indicate that EGR1 and DCN expression,
respectively, increased significantly in the presence of bFGF2
and TGFβ3 with and without LLLT treatment (combination n.
5). The level of the TNC gene (Fig. 3b) appears to be influ-
enced by treatment with bFGF2, TGFβ3 and LLLT (combi-
nation n. 6) since its expression increased significantly,
Fig. 1 Detection of Cluster of Differentiation (CD) markers of peripheral
blood cells using a flow cytometry assay. Peripheral Blood-MSCs (PB-
MSCs) tested at P5 (a) and P10 (b) showed a positivity for antibodies
against CD29, CD44 and CD90 (in blue) and a negativity for Mo/Ma,
MHCII and CD45 (in red). The table shows the average expression ±
standard deviation of CD positivity and negativity of PB-MSCs at P5 and
P10. Control isotypes were tested for each marker to define the threshold
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whereas, treatment with bFGF2 and TGFβ3 without LLLT
showed a similar, but not-significant increasing trend. The
factors bFGF2-EGF2 and bFGF2-IGF1 did not cause varia-
tions in EGR1, DCN and TNCmRNA levels in comparison to
control PB-MSCs (Table 1).
Discussion
Novel treatments used for tendon regeneration include PRP,
MSCs and LLLT. Unfortunately, these methods do not typi-
cally result in complete healing of injured tendons and a return
to total function is very difficult to achieve (Liu et al. 2011).
Obtaining in vitro functional tenocytes from MSCs is impor-
tant for tissue healing and engineering applications (Bi et al.
2007; Tan et al. 2012). We have hypothesized that a specific
mixture of GFs in combination with LLLT induced the differ-
entiation of MSCs towards a tenogenic fate.
TheMSCs used in this study were obtained from peripheral
blood (PB) of healthy horses (n = 4) and the cells were sub-
jected to flow cytometric analysis for characterization. In the
present study it was chosen to use the allogeneic PB-MSCs
between P5 and P10 due to the insufficient cell yield at earlier
passages and in order to generate multiple doses and perform
all necessary quality assessments (Broeckx et al. 2014c;
Vandenbergh et al. 2016).
PB-derived MSCs showed a positive expression for adhe-
sion and the MSC markers CD29, CD44 and CD90, both at
passage P5 and P10. In contrast, PB-MSCs were not positive
for the hematopoietic lineage marker CD45, the monocyte/
macrophage (Mo/Ma) leukocyte markers and MHC II. The
present results showed that PB-MSCs did not lose their stem
markers and the cells maintained their proliferative capacity
through P10 after an initial lag phase.
In experimental studies conducted in vivo, LLLT produced
an anti-inflammatory effect by decreasing the number of fi-
broblasts and neovascularization in tendon lesions of sheep
Fig. 2 The histogram shows the average ± SD of the cell number counted
after different treatments. The number of alive cells is rapresented by light
grey bars while the number of dead cells is indicated by dark grey bars. The
treatments did not modify the cell mortality while influenced the
proliferation activity. Asterisk indicates significant differences (*P < 0.05)
Fig. 3 mRNA expression of EGR1 (early growth response protein 1), TNC
(tenascin c) and DCN (decorin) in PB-MSCs before treatment (Exp) and
after different treatments (Exp L: laser treated cells; F: bFGF2; FL: bFGF2 +
laser; FT: bFGF2 + TGFβ3; FTL: bFGF2 + TGFβ3 + laser; FI: bFGF2 +
IGF1; FIL: bFGF2 + IGF + laser; FE: bFGF2 + EGF2; FEL: bFGF2 +
EGF2 + laser) detected by Real-Time PCR. Each graph rappresents the
average ± SD of cells isolated from four hoses and Exp sample was used
as calibrator. Asterisk indicates significant differences (*P < 0.05)
Table 1 Primers used for the quantitative Real time- PCR analysis
Gene 5′ Forward primer 3′ 5′ Reverse primer 3′
GAPDH gcatcgtggagggactca gccacatcttcccagagg
EGR1 cggacatgacaacaaccttttc cctttgccctttcctttagca
DCN gagagctgcgtgtccatgag agtgggttggtgccaagttc
TNC catccaccatcatccaggagtt tggcaaacacacggatgaa
GAPDH (glyceraldehyde- 3- phosphate dehydrogenase); EGR1 (early
growth response protein 1); DCN (decorin); TNC (tenascin C)
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included in the study (Iacopetti et al. 2015). In addition, LLLT
used on tendinopathies in rats reduced the mRNA expression
of pro-inflammatory mediators such as TNFa (tumor necrosis
factors), IL1b and IL6 (interleukin), and TGFβ (Pires et al.
2011). It is important to precise here that in vivo studies in-
clude many variables and, therefore, the contribution of LLLT
is very difficult to understand. In vitro Huertas et al. (2014)
observed a correlation between the energy density applied and
cell growth rate while Pyo et al. (2013) attributed an increase
in osteoblastic BMP2 (bone morphogenetic protein) and
TGFβ1 expression to LLLT. In the latter study, it is possible
to comment that LLLT induces a general increase of the su-
perfamily TGF-β (BMPs are a subfamily of TGF-β) because
it probably stimulates cell proliferation in regenerative pro-
cesses. Surely, diverse energy densities differently stimulate
cellular metabolic processes (i.e. increasing the oxidation, as
discussed by Hamblin and Demidova 2006) and in our in vitro
experiments a density that should influence cellular
proliferation/differentiation was used, as previously observed
in myoblasts (Monici et al. 2013). Several studies have dem-
onstrated the involvement of bFGF2 in regulating cell growth
and differentiation (Hoffmann and Gross 2007). In this regard,
Cai et al. (2013) indicated that bFGF2 is able to activate the
MAPK pathway promoting the differentiation of MSCs into
tendons. In fact, the expression of bFGF2 induced tendon
matrix protein collagen type I, collagen type III and scleraxis
expression. Furthermore, it was demonstrated that bFGF2,
introduced with a viral vector, modulated the expression of
genes for multiple GFs, increased the gene level of TGF-β1,
CTGF and VEGF and down-regulated IGF1 during the ten-
don repair process (Tang et al. 2014). Overall, bFGF2 has
been reported as the most potent growth stimulator among
the various GFs (Takehara 2000) and it also plays a pivotal
role in wound repair (Molloy et al. 2003). However, in the
present study, bFGF2 alone was not sufficient to induce a
significant increase of expression of EGR1, TNC and DNC.
Therefore, we evaluated the synergic action of bFGF2 in com-
bination with TGFβ3, IGF1 or EGF2 to promote an increase
of those tenogenic genes.
TGFβ is a well-known cytokine that regulates various pro-
cesses in tendon healing. Increased TGFβ levels are associat-
ed with tendon adhesion (Khan et al. 2000) as well as
t end inos i s (Fu e t a l . 2002) . TGFβ i s a ma jo r
anti-proliferative and pro-differentiation signal for hematopoi-
etic stem/progenitor cells (Zhao and Chen 2014). Decreased
TGFβ expression reduces migration and proliferation of
keratinocytes (Hameedaldeen et al. 2014) and the addition of
TGFβ decreases the number of tendon sheath, epitenon and
endotenon cells in culture (Klein et al. 2002). Our results
confirm the anti-proliferative activity of TGFβ3 in
PB-MSCs. In fact, this GF decreased significantly the cellular
proliferation but it did not modify cell death respect other GF
treatments. The activation of a mechanism of cellular
differentiation of PB-MSCs towards the tenogenic fate is hy-
pothesized. Moreover, our results are supported by Rider et al.
(2008), which demonstrated that TGFβ3 inhibits endogenous
bFGF activity for human adipose stem cells (hASCs) prolif-
eration. In 3D culture this GF increased the expression of
TNC, COL1 (collagen 1), COMP (cartilage oligomeric matrix
protein) and Tenomodulin (Barsby et al. 2014).
For the first time in equine MSCs, the genes EGR1, TNC
and DCNwere evaluated with the exogenous addition of GFs.
TGFβ3, IGF1 and EGF2 were tested individually (data not
shown) but, as described by Schneider et al. (2011), were not
able to increase genes involved in the tenogenic pathway.
On the contrary, the combination of bFGF2 and TGFβ3
significantly upregulated the expression of EGR1 and DCN
while the use of LLLT induced a significant increase in TNC
levels. The EGR1 is one of the first transcription factors in-
volved in the tenogenic cascade; it is associated with increased
collagen formation during embryonic tenogenesis and induces
Scleraxis (SCX) and Col1a1 genes (Lejard et al. 2011). TNC
although rarely present in most adult tissues is upregulated in
embryonic and developing tissues or in tissues experiencing a
fast rate of growth and influences cell adhesion and migration
(Goncalves et al. 2013). DCN is a proteoglycan that regulates
tendon structure by stabilizing and aligning collagen fibrils
(Zhang et al. 2006).
The combination of bFGF2-IGF1 and bFGF2-EGF2 did
not alter the expression of EGR1, TNC and DCN in treated
PB-MSC versus control cells. In this case, the addition of
LLLT to GF treatments did not promote the stimulation of
EGR1, DCN and TNC tendon markers. Moreover, the com-
bination bFGF2-IGF1 and bFGF2-EGF2 induced a level of
proliferation activity similar to untreated MSCs, although
IGF1 and EGF2 are known for their proliferative and differ-
entiating effects. EGF2 is a single-chain polypeptide that has
the ability to enhance migration and cell proliferation of bone
marrow derived MSCs (Tamama et al. 2006), and has been
well documented for its mitogenic and chemotactic effects on
fibroblasts (Brown et al. 1991). Regarding IGF1, it is known
that it has a stimulating effect on collagen synthesis in
tendon-ligament tissue since it stimulates fibroblast prolifera-
tion and synthesis of extracellular matrix protein (Durgam
et al. 2012; Hansen et al. 2013). Most likely, in our study,
the effect of IGF1 on tenogenic induction was not seen be-
cause the use of bFGF2 treatment might have down-regulated
its expression (Tsubone et al. 2004).
Conclusions
The effects of GFs on cell cultures are conditioned by numer-
ous variables, such as concentration and timing of incubation,
combination of GFs, evaluated markers and cell type.
However, we consider that this study might furnish significant
Vet Res Commun (2016) 40:39–48 45
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suggestions for developing an efficient approach for tenogenic
induction since from our results, the external administration of
bFGF2 and TGFβ3, along with LLLT, surely optimize and
accelerate the differentiation of PB-MSCs.
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